A Study of LY2510924 and Durvalumab in Participants With Solid Tumors
I2V-MC-CXAD - ClinicalTrials.gov - NCT02737072
The main purpose of this study is to evaluate the safety and tolerability of chemokine (C-X-C Motif) receptor 4 (CXCR4) peptide antagonist LY2510924 and durvalumab for phase 1a and 1b in participants with advanced refractory solid tumors.
Trial Summary
Age Range
≥18 yearsConditions the trial is for
What the trial is testing?
Could I receive a Placebo?
NoEnrollment Goal
9Trial Dates
Sep 1, 2016 - Sep 25, 2017How long will I be in the trial?
The duration of your participation depends on how well your disease responds to the study treatment.Trial Phase
ILilly Trial Alerts
Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.
You will complete the questionnaire on another website.YesNo